We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00814710
First Posted: December 25, 2008
Last Update Posted: November 16, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
Results First Submitted: October 21, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Single (Participant);   Primary Purpose: Prevention
Condition: Infections, Streptococcal
Interventions: Biological: Pneumococcal conjugate vaccine GSK1024850A
Biological: Tritanrix-HepB/Hib
Biological: Hiberix
Biological: Tritanrix-HepB

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Synflorix and Tritanrix-HepB/Hib Group Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
Hiberix Group and Tritanrix-HepB Group Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)

Participant Flow:   Overall Study
    Synflorix and Tritanrix-HepB/Hib Group   Hiberix Group and Tritanrix-HepB Group
STARTED   240   120 
COMPLETED   232   117 
NOT COMPLETED   8   3 
Adverse Event                1                0 
Lost to Follow-up                7                3 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Synflorix and Tritanrix-HepB/Hib Group Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
Hiberix Group and Tritanrix-HepB Group Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
Total Total of all reporting groups

Baseline Measures
   Synflorix and Tritanrix-HepB/Hib Group   Hiberix Group and Tritanrix-HepB Group   Total 
Overall Participants Analyzed 
[Units: Participants]
 240   120   360 
Age 
[Units: Weeks]
Mean (Standard Deviation)
 6.7  (1.08)   6.7  (1.05)   6.7  (1.07) 
Gender 
[Units: Participants]
     
Female   109   66   175 
Male   131   54   185 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes   [ Time Frame: One month after primary immunization (month 3) ]

2.  Primary:   Concentration of Antibody Against Protein D (PD)   [ Time Frame: One month after primary immunization (month 3) ]

3.  Secondary:   Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Serotypes   [ Time Frame: One month after primary immunization (month 3) ]

4.  Secondary:   Number of Subjects With Antibody Concentrations Against Pneumococcal Serotypes Equal to or Above Cut-off Value   [ Time Frame: One month after primary immunization ]

5.  Secondary:   Concentrations of Antibodies Against Pneumococcal Cross-reactive Serotypes   [ Time Frame: One month after primary immunization (month 3) ]

6.  Secondary:   Number of Subjects Seropositive for Pneumococcal Serotypes   [ Time Frame: One month after primary immunization (month 3) ]

7.  Secondary:   Number of Subjects Seropositive for Protein D (PD)   [ Time Frame: One month after primary immunization (month 3) ]

8.  Secondary:   Concentration of Antibody Against Polyribosyl-ribitol Phosphate (PRP)   [ Time Frame: One month after primary immunization (month 3) ]

9.  Secondary:   Concentration of Antibodies Against Diphteria (Anti-DT) and Tetanus (Anti-TT)   [ Time Frame: One month after primary immunization (month 3) ]

10.  Secondary:   Concentration of Antibody Against Bordetella Pertussis (B. Pertussis)   [ Time Frame: One month after primary immunization (month 3) ]

11.  Secondary:   Concentration of Antibody Against Hepatitis B (Anti-HBs)   [ Time Frame: One month after primary immunization (month 3) ]

12.  Secondary:   Number of Subjects Seropostive for B. Pertussis   [ Time Frame: One month after primary immunization (month 3) ]

13.  Secondary:   Number of Seroprotected Subjects (Anti-DT, Anti-TT, Anti-PRP, Anti-HBs)   [ Time Frame: One month after primary immunization (month 3) ]

14.  Secondary:   Number of Seroprotected Subjects (Anti-PRP Above the Cut-off of 1.0 µg/mL)   [ Time Frame: One month after primary immunization (month 3) ]

15.  Secondary:   Number of Subjects With Solicited Local and General Symptoms   [ Time Frame: Within 4 days (day 0-3) after vaccination ]

16.  Secondary:   Number of Subjects With Unsolicited Adverse Events (AEs)   [ Time Frame: Within 31 days (day 0-30) after vaccination ]

17.  Secondary:   Number of Subjects With Serious Adverse Events (SAEs)   [ Time Frame: Following first vaccination (Month 0) throughout the entire study period (month 3) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343


Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00814710     History of Changes
Other Study ID Numbers: 111188
First Submitted: December 23, 2008
First Posted: December 25, 2008
Results First Submitted: October 21, 2010
Results First Posted: October 29, 2010
Last Update Posted: November 16, 2016